|Articles|December 22, 2014

Treatment of Bloodstream Infections in ICUs

Bloodstream infections (BSIs) are frequent in the intensive care unit (ICU) and is a prognostic factor of severe sepsis. Community-acquired BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare-associated BSIs frequently due to resistant hospital strains. Early adequate treatment is key and should use guidelines and direct examination of samples performed from the infectious source. Previous antibiotic therapy knowledge, history of multidrug-resistant organism (MDRO) carriage are other major determinants of first choice antimicrobials in heathcare-associated and nosocomial BSIs. Initial antimicrobial dose should be adapted to pharmacokinetic knowledge. In general, a high dose is recommended at the beginning of treatment.

If presence of MDROs is suspected, combination antibiotic therapy is mandatory because it increase the spectrum of treatment. Most of the time, combination should be pursued no more than two to five days.

Given the negative impact of useless antimicrobials, maximal effort should be done to decrease the antibiotic selection pressure. De-escalation from a broad spectrum to a narrow spectrum antimicrobial decreases the antibiotic selection pressure without negative impact on mortality. Duration of therapy should be shortened as often as possible especially when organism is susceptible, when the infection source has been totally controlled. This research by Timsit, et al. (2014) was published in BMC Infectious Diseases. 

Reference: Timsit J-F, Soubirou J-F, Voiriot G, Chemam S, Neuville M, Mourvillier B, Sonneville R, Mariotte E, Bouadma L and Wolff M. Treatment of bloodstream infections in ICUs. BMC Infectious Diseases 2014, 14:489. doi:10.1186/1471-2334-14-489


Related to this article

Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.